Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-d84b65577b31a872cd6279c4e28cb6f8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-d84b65577b31a872cd6279c4e28cb6f8"/>
<resource>
<Composition>
<id value="composition-en-d84b65577b31a872cd6279c4e28cb6f8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-d84b65577b31a872cd6279c4e28cb6f8"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-d84b65577b31a872cd6279c4e28cb6f8</b></p><a name="composition-en-d84b65577b31a872cd6279c4e28cb6f8"> </a><a name="hccomposition-en-d84b65577b31a872cd6279c4e28cb6f8"> </a><a name="composition-en-d84b65577b31a872cd6279c4e28cb6f8-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/04/281/003</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - erbitux</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/04/281/003"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpd84b65577b31a872cd6279c4e28cb6f8"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - erbitux"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Erbitux is and what it is used for</li><li>What you need to know before you use Erbitux</li><li>How to use Erbitux</li><li>Possible side effects</li><li>How to store Erbitux</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What erbitux is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What erbitux is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Erbitux is</p><p>Erbitux contains cetuximab, a monoclonal antibody. Monoclonal antibodies are proteins that specifically recognise and bind to other unique proteins called antigens. Cetuximab binds to the epidermal growth factor receptor (EGFR), an antigen on the surface of certain cancer cells. EGFR activates proteins called RAS. RAS proteins play an important role in the EGFR pathway a complex signalling cascade which is involved in the development and progression of cancer. As a result of this binding, the cancer cell can no longer receive the messages it needs for growth, progression and metastasis.</p><p>What Erbitux is used for</p><p>Erbitux is used to treat two different types of cancer:</p><ul><li><p>metastatic cancer of the large intestine. In these patients, Erbitux is used alone or in combination with other anticancer medicines.</p></li><li><p>a certain type of cancer of the head and neck (squamous cell cancer). In these patients, Erbitux is used in combination with radiation therapy or with other anticancer medicines.</p></li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take erbitux"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take erbitux"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Erbitux</p><p>Do not use Erbitux if you have ever had a severe hypersensitivity (allergic) reaction to cetuximab.</p><p>Before starting treatment for metastatic cancer of the large intestine your doctor will test your cancer cells if they contain the normal (wild-type) or mutant form of RAS. You must not receive Erbitux in combination with other anticancer treatment containing oxaliplatin if your cancer cells contain the mutant form of RAS.</p><p>Warnings and precautions</p><p>Talk to your doctor before using Erbitux, if any of the following information is not clear.</p><p>Erbitux may cause infusion-related side effects. Such reactions may be allergic in nature. Please read 'Infusion-related side effects' in section 4 for details, as they may have serious consequences for you, including life-threatening conditions. These side effects normally occur during the infusion, within 1 hour afterwards, or sometimes also after this period. To recognise early signs of such effects, your condition will be checked regularly while you receive each infusion of Erbitux and for at least 1 hour afterwards. You are more likely to experience severe allergic reactions if you are allergic to red meat, tick bites or had positive results for certain antibodies (seen in a test). Your doctor will discuss appropriate measures with you.</p><p>Erbitux may cause side effects concerning the skin. Your doctor will discuss with you whether you may need any preventive measures or early treatment. Please also read 'Side effects concerning the skin' in section 4 for details, as some skin reactions may have serious consequences for you, including life-threatening conditions.</p><p>If you have heart problems, your doctor will discuss with you whether you can receive Erbitux in combination with other anticancer medicines, especially if you are 65 years of age or older. Erbitux may cause side effects concerning the eyes. Please tell your doctor, if you have acute or worsening eye problems such as blurred vision, eye pain, red eyes and/or severe dry eye, if you have had such problems in the past or if you use contact lenses. Your doctor will discuss with you whether you need to consult a specialist.</p><p>If you receive Erbitux in combination with anticancer medicines including platinum, it is more likely that your white blood cell count may be reduced. Your doctor will therefore monitor your blood and general condition for signs of infection (see also 'Side effects in combination with other anticancer treatments' in section 4).</p><p>If you receive Erbitux in combination with other anticancer medicines, including fluoropyrimidines, it may be more likely that you experience heart problems which may be life-threatening. Your doctor will discuss with you whether you may need any particular supervision (see also 'Side effects in combination with other anticancer treatments' in section 4).</p><p>Children and adolescents</p><p>There is no relevant use of Erbitux in children and adolescents.</p><p>Other medicines and Erbitux</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Pregnancy</p><p>Tell your doctor if you are pregnant or if you are not using reliable contraception (speak to your doctor if you are not sure). Your doctor will then discuss with you the risks and benefits of using Erbitux in these situations.</p><p>Breast-feeding</p><p>Do not breast-feed your baby during the period over which you are being treated with Erbitux and for two months after the last dose.</p><p>Driving and using machines</p><p>Do not drive or use any tools or machines if you experience treatment-related symptoms that affect your ability to concentrate and react.</p></div>
</text>
</section>
<section>
<title value="3. How to take erbitux"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take erbitux"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>A doctor experienced in the use of anticancer medicines will supervise your Erbitux therapy. During each infusion and for at least 1 hour afterwards, your condition will be checked regularly for early signs of a possible infusion-related side effect.</p><p>Pre-treatment</p><p>Before the first dose, you will receive an antiallergic medicine in order to reduce the risk of an allergic reaction. Your doctor will decide whether such pre-treatment is necessary for subsequent doses.</p><p>Dosage and administration</p><p>Erbitux is usually infused into a vein (given as a drip) once a week. Your doctor will calculate the correct dose of Erbitux for you because it depends on your body surface area. The first dose (400 mg/m body surface area) is infused over a period of approximately 2 hours with an infusion rate not faster than 5 mg/min. Each subsequent dose (250 mg/m body surface area) is infused in approximately 1 hour with an infusion rate not faster than 10 mg/min.</p><p>Detailed instructions for your doctor or your nurse on how to prepare the Erbitux infusion are included at the end of this package leaflet (see 'Handling instructions').</p><p>Duration of treatment</p><p>Erbitux is usually infused once a week. The duration of treatment may vary depending on your disease as well as from person to person and your doctor will therefore discuss with you how long you will receive Erbitux.</p><p>Combination with other anticancer treatments</p><p>If you receive Erbitux in combination with other anticancer medicines, these medicines must be administered at least 1 hour after the end of the Erbitux infusion.</p><p>If you receive Erbitux in combination with radiation therapy, treatment with Erbitux is usually started one week before radiation therapy.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The main side effects of Erbitux are infusion-related side effects and side effects concerning the skin:</p><p>Infusion-related side effects</p><p>More than 10 out of 100 patients are likely to experience infusion-related side effects; in more than 1 out of 100 patients these side effects are likely to be severe. Such reactions may be allergic in nature. They normally occur during the infusion, within 1 hour afterwards, or sometimes also after this period.</p><p>Mild or moderate infusion-related side effects include:</p><ul><li>fever</li><li>chills</li><li>dizziness</li><li>breathing difficulties<br/>If such symptoms occur, please inform your doctor as soon as possible. Your doctor may consider reducing the infusion rate of Erbitux to manage these symptoms.</li></ul><p>Severe infusion-related side effects include:</p><ul><li>severe breathing difficulties which develop rapidly</li><li>hives</li><li>fainting</li><li>chest pain (a symptom of side effects on your heart) If such symptoms occur, speak to a doctor immediately. These side effects may have serious consequences, in rare cases including life-threatening conditions, and require immediate attention. Treatment with Erbitux must then be stopped.</li></ul><p>Side effects concerning the skin</p><p>More than 80 out of 100 patients are likely to experience side effects involving the skin. In about out of 100 patients these skin reactions are likely to be severe. Most of these side effects develop within the first three weeks of treatment. They usually disappear over time after the end of Erbitux therapy.</p><p>Main side effects concerning the skin include:</p><ul><li>acne-like skin alterations</li><li>itching</li><li>dry skin</li><li>scaling</li><li>excessive growth of hair</li><li>nail disorders, for example inflammation of the nail bed</li></ul><p>In very rare cases (may affect up to 1 in 10,000 people) patients may experience blistering or peeling of the skin, which may indicate a severe skin reaction called Stevens-Johnson syndrome . If you experience these symptoms, please speak to a doctor immediately, because these signs may have serious consequences including life-threatening conditions.</p><p>If you notice other extensive skin alterations, please inform your doctor as soon as possible because the Erbitux dose or the time between infusions may need to be changed. Your doctor will decide whether treatment has to be stopped if skin reactions reappear after several dose reductions.</p><p>If you notice that already affected areas of your skin get worse, speak to a doctor immediately, especially if you also experience general signs of infection such as fever and tiredness. These signs may indicate a skin infection, which may have serious consequences including life-threatening conditions.</p><p>Side effects concerning the lungs</p><p>In uncommon cases (may affect up to 1 in 100 people) patients may experience an inflammation of the lungs (called interstitial lung disease), which may have serious consequences including life- threatening conditions.</p><p>If you notice symptoms such as occurrence or worsening of breathing difficulties, speak to a doctor immediately, especially if you also experience cough or fever. Your doctor will decide whether treatment has to be stopped.</p><p>Other side effects</p><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>inflammation of the lining of the intestine, mouth, and nose (in some cases severe), which may lead to nose bleeding in some patients</li><li>decrease in blood levels of magnesium</li><li>increase in blood levels of certain liver enzymes</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>headache</li><li>tiredness</li><li>irritation and redness of the eye</li><li>diarrhoea</li><li>drying out which may be due to diarrhoea or reduced fluid intake</li><li>feeling sick</li><li>vomiting</li><li>loss of appetite, leading to weight decrease</li><li>decrease in blood levels of calcium</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>blood clots in the veins of the legs</li><li>blood clots in the lungs</li><li>inflammation of the eye lid or the front part of the eye</li></ul><p>Side effects of which the frequency is not known (cannot be estimated from the available data)</p><ul><li>inflammation of the lining of the brain (aseptic meningitis)</li></ul><p>Side effects in combination with other anticancer treatments</p><p>If you receive Erbitux in combination with other anticancer medicines, some of the side effects you may experience can also be related to the combination or the other medicines. Therefore, please make sure that you also read the package leaflet for the other medicines.</p><p>If you receive Erbitux in combination with anticancer medicines including platinum, it is more likely that your white blood cell count may be reduced. This may lead to infectious complications including life-threatening conditions, especially if you experience skin reactions, inflammation of the lining of the intestine and mouth or diarrhoea. Therefore, if you experience general signs of infection such as fever and tiredness, please speak to a doctor immediately.</p><p>If you receive Erbitux in combination with an anticancer medicine containing fluoropyrimidines, it is more likely that you experience the following side effects of this other medicine:</p><ul><li>chest pain</li><li>heart attack</li><li>heart failure</li><li>redness and swelling of the palms of the hands or the soles of the feet which may cause the skin to peel (hand-foot syndrome)</li></ul><p>If you receive Erbitux with radiation therapy, some of the side effects you may experience can also be related to this combination, such as:</p><ul><li>inflammation of the lining of the intestine and mouth</li><li>skin reactions typical for radiation therapy</li><li>difficulty in swallowing</li><li>reduction in the number of white blood cells</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store erbitux"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store erbitux"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C 8 C). Once opened, Erbitux is intended for immediate use.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Erbitux contains</p><ul><li>The active substance is cetuximab. Each mL of the solution for infusion contains 5 mg cetuximab. Each vial of 20 mL contains 100 mg cetuximab. Each vial of 100 mL contains 500 mg cetuximab.</li><li>The other ingredients are sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide and water for injections.</li></ul><p>What Erbitux looks like and contents of the pack</p><p>Erbitux 5 mg/mL solution for infusion is supplied in vials containing 20 mL or 100 mL. Each pack contains 1 vial.</p><p>Not all vial sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Merck Europe B.V. Gustav Mahlerplein 1082 MA Amsterdam The Netherlands</p><p>Manufacturer</p><p>Merck Healthcare KGaA Frankfurter Stra e 64293 Darmstadt Germany</p><p>This leaflet was last revised in MM/YYYY.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpd84b65577b31a872cd6279c4e28cb6f8"/>
<resource>
<MedicinalProductDefinition>
<id value="mpd84b65577b31a872cd6279c4e28cb6f8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpd84b65577b31a872cd6279c4e28cb6f8"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpd84b65577b31a872cd6279c4e28cb6f8</b></p><a name="mpd84b65577b31a872cd6279c4e28cb6f8"> </a><a name="hcmpd84b65577b31a872cd6279c4e28cb6f8"> </a><a name="mpd84b65577b31a872cd6279c4e28cb6f8-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/04/281/003</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Erbitux 5 mg/mL solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/04/281/003"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Erbitux 5 mg/mL solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
